Send to

Choose Destination
J Natl Compr Canc Netw. 2013 Nov;11(11):1327-40.

Chronic Myelogenous Leukemia, Version 1.2014.

Author information

From 1The University of Texas MD Anderson Cancer Center; 2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 5Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 6Memorial Sloan-Kettering Cancer Center; 7Dana-Farber/Brigham & Women's Cancer Center; 8Huntsman Cancer Institute at the University of Utah; 9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 10Massachusetts General Hospital Cancer Center; 11Stanford Cancer Institute; 12Vanderbilt-Ingram Cancer Center; 13Fox Chase Cancer Center; 14Duke Cancer Institute; 15St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 16Moffitt Cancer Center; 17University of Alabama at Birmingham Comprehensive Cancer Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 20City of Hope Comprehensive Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.


The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Sheridan PubFactory Icon for PubMed Central
Loading ...
Support Center